Ibritumomab tiuxetan is a medication used in the treatment of certain types of non-Hodgkin's lymphoma, a type of cancer that affects the lymphatic system. Let's break down what Ibritumomab tiuxetan is, how it works, and why it's used in simple terms.
Firstly, Ibritumomab tiuxetan is a type of targeted therapy called radioimmunotherapy. This means that it combines the properties of a monoclonal antibody with a radioactive substance to specifically target and destroy cancer cells.
Imagine your body's immune system as an army that defends against invaders like bacteria and viruses. Sometimes, cancer cells can disguise themselves and evade detection by the immune system. This is where Ibritumomab tiuxetan comes in.
Ibritumomab tiuxetan is like a guided missile that seeks out and attaches to a protein called CD20, which is found on the surface of certain white blood cells called B cells. In non-Hodgkin's lymphoma, these B cells become cancerous and multiply uncontrollably.
Once attached to the CD20 protein, Ibritumomab tiuxetan delivers a dose of radiation directly to the cancer cells. This radiation damages the DNA inside the cancer cells, preventing them from dividing and eventually causing them to die.
One of the advantages of Ibritumomab tiuxetan is that it can target cancer cells while sparing healthy cells as much as possible. This can result in fewer side effects compared to traditional chemotherapy, which can affect both cancerous and healthy cells.
Ibritumomab tiuxetan is usually given as an infusion into a vein, typically in a hospital or clinic setting. The dosage and frequency of treatment depend on factors like the type and stage of non-Hodgkin's lymphoma, as well as the individual's overall health.
Like any medication, Ibritumomab tiuxetan isn't without risks. Some common side effects include low blood cell counts, fatigue, nausea, and vomiting. These side effects are usually temporary and can often be managed with proper medical care.
In summary, Ibritumomab tiuxetan is a targeted therapy used in the treatment of non-Hodgkin's lymphoma by specifically targeting and destroying cancer cells while sparing healthy cells as much as possible. While it can be effective in treating this type of cancer, it's essential for patients to discuss potential benefits and risks with their doctors before starting treatment. Ibritumomab tiuxetan offers hope for individuals battling non-Hodgkin's lymphoma and provides another option in the fight against cancer.
Have any queries, book a consultation with our Oncology Clinical Specialist
top of page
₹500.00Price
bottom of page